Interventional Cardiology Devices: World Market Prospects 2011-2021
Our latest pharma report - Interventional Cardiology Devices: World Market Prospects 2011-2021 - offers a comprehensive view of the global interventional cardiology devices market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the interventional cardiology devices market in 2011 to be worth $10.6bn. Growth in this market will be driven by new technology such as, bioabsorbable stents, drug-eluting balloons and optical coherence tomography.
Interventional cardiology is one of the fastest growing sectors of the medical device market. Interventional cardiology is a branch of cardiology that deals with catheter based treatments of heart diseases and defects. This involves insertion of a catheter usually into the femoral artery. However, it is possible to use any large peripheral artery or vein. The market has significant potential for growth with the increasing global burden of coronary artery disease, especially in the emerging economies.
Visiongain's research suggests that the interventional cardiology devices market will benefit from the growth of healthcare markets in the emerging economies. Increasing wealth in China and India will lead to an increase in lifestyle related disorders such as diabetes and coronary artery disease. At the same time, mature markets such as the US and Japan will also experience growth, albeit slow, restrained by some regulatory and reimbursement issues discussed in detail in the report.
Interventional Cardiology Devices: World Market Prospects 2011-2021 examines the coronary stent, PTCA balloon and intravascular imaging markets, with respect to the market size, leading companies and products, and promising products in the pipeline. Visiongain predicts that this market will grow steadily to 2021, primarily driven by technological innovation and new products reaching the market.
How will the interventional cardiology devices market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the interventional cardiology devices submarkets are growing most strongly? Who are the leading companies in the interventional cardiology devices market? What are the most promising interventional cardiology devices in development and when are they expected to receive market approval?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Detailed analysis of the global Interventional Cardiology Devices Market
Interventional Cardiology Devices: World Market Prospects 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 93 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Interventional Cardiology Devices: World Market Prospects 2011-2021
In this report, you will receive the following benefits in particular:
Anybody with an interest in the interventional cardiology industry should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important cardiology devices industries. Success in the cardiology devices market from 2011 to 2021 will be characterised by the growth of interventional cardiology devices market and launch of innovative products currently in the pipeline. You can find out about the developments in this industry and much more from this latest report from visiongain on Interventional Cardiology Devices: World Market Prospects 2011-2021. You can stay ahead by ordering this report today.
Interventional cardiology is one of the fastest growing sectors of the medical device market. Interventional cardiology is a branch of cardiology that deals with catheter based treatments of heart diseases and defects. This involves insertion of a catheter usually into the femoral artery. However, it is possible to use any large peripheral artery or vein. The market has significant potential for growth with the increasing global burden of coronary artery disease, especially in the emerging economies.
Visiongain's research suggests that the interventional cardiology devices market will benefit from the growth of healthcare markets in the emerging economies. Increasing wealth in China and India will lead to an increase in lifestyle related disorders such as diabetes and coronary artery disease. At the same time, mature markets such as the US and Japan will also experience growth, albeit slow, restrained by some regulatory and reimbursement issues discussed in detail in the report.
Interventional Cardiology Devices: World Market Prospects 2011-2021 examines the coronary stent, PTCA balloon and intravascular imaging markets, with respect to the market size, leading companies and products, and promising products in the pipeline. Visiongain predicts that this market will grow steadily to 2021, primarily driven by technological innovation and new products reaching the market.
How will the interventional cardiology devices market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the interventional cardiology devices submarkets are growing most strongly? Who are the leading companies in the interventional cardiology devices market? What are the most promising interventional cardiology devices in development and when are they expected to receive market approval?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Detailed analysis of the global Interventional Cardiology Devices Market
Interventional Cardiology Devices: World Market Prospects 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 93 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Interventional Cardiology Devices: World Market Prospects 2011-2021
In this report, you will receive the following benefits in particular:
- You will receive our assessment of the current market for interventional cardiology devices, with respect to the leading segments, products, companies and national markets
- You will discover sales trends for the overall interventional cardiology devices market from 2011 to 2021 - seeing where commercial growth will occur
- You will discover sales trends for the main segments - coronary stents, PTCA balloons and intravascular imaging markets - from 2011 to 2021, with detailed discussions of market potential
- You will receive sales forecasts for leading geographical markets (US, Japan, Germany, France, Italy, Spain, UK, China and India), with informed discussion
- You will assess leading companies in the interventional cardiology devices market along with rankings for each company, with regards to global sales in 2010
- You will receive our analyses of the future of interventional cardiology devices market, including assessment of the R&D pipelines in the coronary stent, PTCA balloon and intravascular imaging segments
- You will examine the strengths, weaknesses, opportunities and threats (SWOT analysis) facing the coronary stent, PTCA balloon and intravascular imaging markets from 2011 onwards
- You will be able to investigate competition and opportunities influencing the interventional cardiology devices market from 2011 onwards
- You will see what will stimulate and restrain the interventional cardiology devices market from 2011
- You will discover the unmet needs in the market, driving the growth from 2011 onwards
- You will view expert opinion from our survey, including full interview transcripts.
Anybody with an interest in the interventional cardiology industry should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important cardiology devices industries. Success in the cardiology devices market from 2011 to 2021 will be characterised by the growth of interventional cardiology devices market and launch of innovative products currently in the pipeline. You can find out about the developments in this industry and much more from this latest report from visiongain on Interventional Cardiology Devices: World Market Prospects 2011-2021. You can stay ahead by ordering this report today.
1. EXECUTIVE SUMMARY
1.1 Interventional Cardiology Devices Market Review
1.2 Overview of Chapter Content
1.3 Research and Analysis Method
1.4 Glossary of Terms Relating to Interventional Cardiology
2. INTRODUCTION TO INTERVENTIONAL CARDIOLOGY
2.1 What is Interventional Cardiology?
2.1.1 Advantages and Disadvantages of Interventional Cardiology
2.2 Coronary Artery Disease (CAD)
2.3 Interventional Cardiology Procedures
2.3.1 Angioplasty
2.3.1.1 Balloon Angioplasty
2.3.1.2 Laser Angioplasty
2.3.2 Coronary Stenting
2.3.2.1 Bare Metal Stents (BMS)
2.3.2.2 Drug Eluting Stents (DES)
2.3.2.2.1 Drugs Used in DES
2.3.3 Intravascular Imaging
2.3.3.1 Intravascular Ultrasound (IVUS)
2.3.3.2 Optical Coherence Tomography (OCT)
2.3.3.3 Fractional Flow Reserve (FFR)
2.4 Regulation of Interventional Cardiology Devices
2.4.1 The US Regulation System
2.4.2 The European Regulation System
2.4.2.1 Post Marketing Surveillance in the EU
3. THE GLOBAL INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2010-2021
3.1 Interventional Cardiology Devices: Market Overview
3.1.1 Size of the Interventional Cardiology Devices Market in 2010
3.2 Regional Market Breakdown, 2010
3.2.1 The US, European and Japanese Markets
3.2.2 The Chinese and Indian Markets
3.3 Global Interventional Cardiology Devices Market Forecast, 2011-2015
3.4 Global Interventional Cardiology Devices Market Forecast, 2015-2021
3.5 Leading National Markets for Interventional Cardiology Devices: Sales Forecasts, 2011-2021
3.5.1 The US, European and Japanese Markets, 2011-2021
3.5.1.1 The US Market
3.5.1.2 The European Markets
3.5.1.3 The Japanese Market
3.5.2 The Chinese and Indian Markets, 2011-2021
3.5.2.1 The Chinese Market
3.5.2.2 The Indian Market
4. THE CORONARY STENT MARKET, 2010-2021
4.1 Chapter Overview
4.1.1 Coronary Stent Market in 2010: Market Segments and Country/Regional Breakdown
4.1.2 Coronary Stent Market Forecast, 2011-2021
4.2 The DES Market
4.2.1 The DES Market in 2010
4.2.2 The DES Market Forecast, 2011-2015
4.2.3 The DES Market Forecast, 2015-2021
4.3 Leading Coronary Stents: Product Analysis
4.3.1 Cypher Sirolimus-Eluting Stent (Cordis, a wholly owned subsidiary of Johnson and Johnson)
4.3.2 Taxus Paclitaxel-Eluting Stent (Boston Scientific)
4.3.2.1 Disputes Over Paclitaxel-Eluting Stents
4.3.3 Promus Everolimus-Eluting Stent (Boston Scientific)
4.3.4 Xience V Everolimus-Eluting Stent (Abbott Vascular)
4.3.5 Endeavor (Medtronic)
4.3.6 BioMatrix (Biosensors International)
4.4 The Coronary Stent Pipeline
4.4.1 Jactax (Boston Scientific)
4.4.2 MiStent (MiCell Technologies)
4.4.3 Synergy (Boston Scientific)
4.4.4 BioFreedom (Biosensors International)
4.4.5 VESTAsync (MIV Therapeutics)
4.4.6 Catania (CeloNova BioSciences)
4.4.7 Genous Combo (OrbusNeich)
4.5 Bioabsorbable Drug Eluting Stents
4.6 SWOT Analysis of the DES Market, 2011-2021
4.6.1 Strengths
4.6.1.1 DES Are More Effective Than BMS
4.6.1.2 Continuous Innovation
4.6.1.3 Continuously-Evolving Market
4.6.2 Weaknesses
4.6.2.1 Stent Thrombosis
4.6.2.2 The Success of DES Compared with Other Treatments
4.6.3 Opportunities
4.6.3.1 Increase in Coronary Artery Disease
4.6.3.2 Moving Away from Dual Antiplatelet Therapy
4.6.4 Threats
4.6.4.1 Small Number of Companies Operating in the US and Japan
4.6.4.2 The Drug May Become More Important Than the Stent
4.6.4.3 The DES Market is Still Emerging
5. THE PTCA BALLOON MARKET, 2010-2021
5.1 PTCA Balloon: Market Overview
5.1.1 PTCA Balloon Market is Dominated by Four Companies, 2010
5.1.2 PTCA Balloon Market Forecast, 2011-2021
5.2 PTCA Balloon Pipeline
5.2.1 Drug Eluting Balloons (DEBs)
5.2.2 DEB Market Forecast, 2011-2021
5.2.3 DEBs Currently in Development
5.2.3.1 ELUTAX (Aachen Resonance)
5.2.3.2 SeQuent Please (B.Braun Melsungen)
5.2.3.3 DIOR (Eurocor)
5.2.3.4 IN.PACT Amphirion (Invatec)
5.2.3.5 Moxy (Lutonix)
5.2.3.6 Pantera Lux (Biotronik)
5.3 SWOT Analysis of the PTCA Balloon Market, 2011-2021
5.3.1 Strengths
5.3.1.1 Well Established, Mature Sector of the Market
5.3.1.2 May Avoid the Need for a Permanent Coronary Stent and Dual Antiplatelet Therapy
5.3.2 Weaknesses
5.3.2.1 Standard PTCA has a High Rate of Restenosis
5.3.2.2 Only a Small Number of Companies Operate in the Market
5.3.3 Opportunities
5.3.3.1 Controversy Regarding Stent Safety
5.3.3.2 Rise in the Number of People with Coronary Artery Disease (CAD)
5.3.4 Threats
5.3.4.1 Drugs and Stents Could Become More Important than PTCA Balloon Procedures
5.3.4.2 The DEB Market is Still Emerging
6. THE INTRAVASCULAR IMAGING MARKET, 2010-2021
6.1 The Intravascular Imaging Market in 2010
6.2 Intravascular Imaging Forecast, 2011-2015
6.3 Intravascular Imaging Forecast, 2015-2021
6.4 Intravascular Imaging Pipeline
6.4.1 Next Generation Imaging Technologies
6.4.1.1 High-Definition Intravascular Ultrasound (Silicon Valley Medical Instruments)
6.4.1.2 High-Resolution MicroOCT (Centre for Photomedicine at Massachusetts General Hospital)
6.4.1.3 Forward Looking Intravascular Ultrasound (FLIVUS) (Volcano Corporation)
6.4.1.4 Virtual Histology Intravascular Ultrasound (VH IVUS) (Volcano Corporation)
6.4.2 Multimodality Imaging
6.4.2.1 Lipiscan (InfraReDx)
6.4.2.2 Intravascular Ultrasound Optical Coherence Tomography Imaging System (University of California at Irvine)
6.4.3 Image Guided Therapies
6.4.3.1 Vibe RX Vascular Imaging Balloon Catheter (Volcano Corporation)
6.5 SWOT Analysis of the Intravascular Imaging Market, 2011-2021
6.5.1 Strengths
6.5.1.1 Provides Cardiologists with Useful Information
6.5.1.2 Higher Resolution Image than Coronary Angiography
6.5.1.3 Strong Intravascular Imaging Pipeline
6.5.2 Weaknesses
6.5.2.1 Expensive Technology That May Limit its Appeal
6.5.2.2 Adds Significant Time and Risk to the Procedure
6.5.3 Opportunities
6.5.3.1 Image Guided Therapy Offers Higher Efficacy than Stenting Alone
6.5.3.2 Increasing Prevalence of Coronary Artery Disease
6.5.4 Threats
6.5.4.1 Small Number of Companies Operate in the Market
6.5.4.2 Low Reimbursement Rates Threaten to Prevent Widescale Use
7. INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ANALYSIS BY COMPANY, 2010
7.1 Boston Scientific
7.1.1 Boston Scientific Interventional Cardiology Sales, 2010
7.1.2 Boston Scientific Interventional Cardiology Rankings, 2010
7.1.3 Boston Scientific Pipeline
7.2 Abbott Vascular
7.2.1 Abbott Vascular Sales, 2010
7.2.2 Abbott Vascular Interventional Cardiology Rankings, 2010
7.2.3 Abbott Vascular Pipeline
7.3 Medtronic
7.3.1 Medtronic Sales, 2010
7.3.2 Medtronic Interventional Cardiology Rankings, 2010
7.3.3 Medtronic Pipeline
7.4 Volcano Corporation
7.4.1 Volcano Corporation Sales, 2010
7.4.2 Volcano Corporation Interventional Cardiology Ranking, 2010
7.4.3 Volcano Corporation Pipeline
7.5 Cordis Corporation (a Johnson & Johnson Company)
7.5.1 Cordis Sales, 2010
7.5.2 Cordis Rankings, 2010
7.5.3 Cordis Pipeline
7.6 St. Jude Medical
7.6.1 St. Jude Medical Sales, 2010
7.6.2 St. Jude Medical Pipeline
8. EXPERT OPINIONS
8.1 Interview with Guillermo Tearney, Professor of Pathology at The Wellman Center for Photomedicine, Harvard Medical School
8.1.1 The Intravascular Imaging Market
8.1.2 The Novel MicroOCT System Currently being Developed by Professor Tearney at Harvard University
8.1.3 The International Working Group for Intracoronary OCT Standardization and Validation
8.2 Interview with Zhongping Chen, Professor of Biomedical Engineering at University of California
8.2.1 The Intravascular Imaging Market
8.2.2 The Combined IVUS/OCT System Currently being Developed by Professor Chen at the University of California
9. CONCLUSIONS
9.1 The Interventional Cardiology Devices Market, 2011-2021
9.1.1 Growth will be Driven by Emerging Markets
9.2 The Coronary Stent Market, 2011-2021
9.2.1 Innovation Will Drive Growth in the DES Market
9.2.2 DES May Be Challenged by Other Stenting Technologies
9.3 The PTCA Balloon Market, 2011-2021
9.3.1 DEBs Will See Rapid Growth
9.4 The Intravascular Imaging Market, 2011-2021
Appendix A
Appendix B
Visiongain report evaluation form
1.1 Interventional Cardiology Devices Market Review
1.2 Overview of Chapter Content
1.3 Research and Analysis Method
1.4 Glossary of Terms Relating to Interventional Cardiology
2. INTRODUCTION TO INTERVENTIONAL CARDIOLOGY
2.1 What is Interventional Cardiology?
2.1.1 Advantages and Disadvantages of Interventional Cardiology
2.2 Coronary Artery Disease (CAD)
2.3 Interventional Cardiology Procedures
2.3.1 Angioplasty
2.3.1.1 Balloon Angioplasty
2.3.1.2 Laser Angioplasty
2.3.2 Coronary Stenting
2.3.2.1 Bare Metal Stents (BMS)
2.3.2.2 Drug Eluting Stents (DES)
2.3.2.2.1 Drugs Used in DES
2.3.3 Intravascular Imaging
2.3.3.1 Intravascular Ultrasound (IVUS)
2.3.3.2 Optical Coherence Tomography (OCT)
2.3.3.3 Fractional Flow Reserve (FFR)
2.4 Regulation of Interventional Cardiology Devices
2.4.1 The US Regulation System
2.4.2 The European Regulation System
2.4.2.1 Post Marketing Surveillance in the EU
3. THE GLOBAL INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2010-2021
3.1 Interventional Cardiology Devices: Market Overview
3.1.1 Size of the Interventional Cardiology Devices Market in 2010
3.2 Regional Market Breakdown, 2010
3.2.1 The US, European and Japanese Markets
3.2.2 The Chinese and Indian Markets
3.3 Global Interventional Cardiology Devices Market Forecast, 2011-2015
3.4 Global Interventional Cardiology Devices Market Forecast, 2015-2021
3.5 Leading National Markets for Interventional Cardiology Devices: Sales Forecasts, 2011-2021
3.5.1 The US, European and Japanese Markets, 2011-2021
3.5.1.1 The US Market
3.5.1.2 The European Markets
3.5.1.3 The Japanese Market
3.5.2 The Chinese and Indian Markets, 2011-2021
3.5.2.1 The Chinese Market
3.5.2.2 The Indian Market
4. THE CORONARY STENT MARKET, 2010-2021
4.1 Chapter Overview
4.1.1 Coronary Stent Market in 2010: Market Segments and Country/Regional Breakdown
4.1.2 Coronary Stent Market Forecast, 2011-2021
4.2 The DES Market
4.2.1 The DES Market in 2010
4.2.2 The DES Market Forecast, 2011-2015
4.2.3 The DES Market Forecast, 2015-2021
4.3 Leading Coronary Stents: Product Analysis
4.3.1 Cypher Sirolimus-Eluting Stent (Cordis, a wholly owned subsidiary of Johnson and Johnson)
4.3.2 Taxus Paclitaxel-Eluting Stent (Boston Scientific)
4.3.2.1 Disputes Over Paclitaxel-Eluting Stents
4.3.3 Promus Everolimus-Eluting Stent (Boston Scientific)
4.3.4 Xience V Everolimus-Eluting Stent (Abbott Vascular)
4.3.5 Endeavor (Medtronic)
4.3.6 BioMatrix (Biosensors International)
4.4 The Coronary Stent Pipeline
4.4.1 Jactax (Boston Scientific)
4.4.2 MiStent (MiCell Technologies)
4.4.3 Synergy (Boston Scientific)
4.4.4 BioFreedom (Biosensors International)
4.4.5 VESTAsync (MIV Therapeutics)
4.4.6 Catania (CeloNova BioSciences)
4.4.7 Genous Combo (OrbusNeich)
4.5 Bioabsorbable Drug Eluting Stents
4.6 SWOT Analysis of the DES Market, 2011-2021
4.6.1 Strengths
4.6.1.1 DES Are More Effective Than BMS
4.6.1.2 Continuous Innovation
4.6.1.3 Continuously-Evolving Market
4.6.2 Weaknesses
4.6.2.1 Stent Thrombosis
4.6.2.2 The Success of DES Compared with Other Treatments
4.6.3 Opportunities
4.6.3.1 Increase in Coronary Artery Disease
4.6.3.2 Moving Away from Dual Antiplatelet Therapy
4.6.4 Threats
4.6.4.1 Small Number of Companies Operating in the US and Japan
4.6.4.2 The Drug May Become More Important Than the Stent
4.6.4.3 The DES Market is Still Emerging
5. THE PTCA BALLOON MARKET, 2010-2021
5.1 PTCA Balloon: Market Overview
5.1.1 PTCA Balloon Market is Dominated by Four Companies, 2010
5.1.2 PTCA Balloon Market Forecast, 2011-2021
5.2 PTCA Balloon Pipeline
5.2.1 Drug Eluting Balloons (DEBs)
5.2.2 DEB Market Forecast, 2011-2021
5.2.3 DEBs Currently in Development
5.2.3.1 ELUTAX (Aachen Resonance)
5.2.3.2 SeQuent Please (B.Braun Melsungen)
5.2.3.3 DIOR (Eurocor)
5.2.3.4 IN.PACT Amphirion (Invatec)
5.2.3.5 Moxy (Lutonix)
5.2.3.6 Pantera Lux (Biotronik)
5.3 SWOT Analysis of the PTCA Balloon Market, 2011-2021
5.3.1 Strengths
5.3.1.1 Well Established, Mature Sector of the Market
5.3.1.2 May Avoid the Need for a Permanent Coronary Stent and Dual Antiplatelet Therapy
5.3.2 Weaknesses
5.3.2.1 Standard PTCA has a High Rate of Restenosis
5.3.2.2 Only a Small Number of Companies Operate in the Market
5.3.3 Opportunities
5.3.3.1 Controversy Regarding Stent Safety
5.3.3.2 Rise in the Number of People with Coronary Artery Disease (CAD)
5.3.4 Threats
5.3.4.1 Drugs and Stents Could Become More Important than PTCA Balloon Procedures
5.3.4.2 The DEB Market is Still Emerging
6. THE INTRAVASCULAR IMAGING MARKET, 2010-2021
6.1 The Intravascular Imaging Market in 2010
6.2 Intravascular Imaging Forecast, 2011-2015
6.3 Intravascular Imaging Forecast, 2015-2021
6.4 Intravascular Imaging Pipeline
6.4.1 Next Generation Imaging Technologies
6.4.1.1 High-Definition Intravascular Ultrasound (Silicon Valley Medical Instruments)
6.4.1.2 High-Resolution MicroOCT (Centre for Photomedicine at Massachusetts General Hospital)
6.4.1.3 Forward Looking Intravascular Ultrasound (FLIVUS) (Volcano Corporation)
6.4.1.4 Virtual Histology Intravascular Ultrasound (VH IVUS) (Volcano Corporation)
6.4.2 Multimodality Imaging
6.4.2.1 Lipiscan (InfraReDx)
6.4.2.2 Intravascular Ultrasound Optical Coherence Tomography Imaging System (University of California at Irvine)
6.4.3 Image Guided Therapies
6.4.3.1 Vibe RX Vascular Imaging Balloon Catheter (Volcano Corporation)
6.5 SWOT Analysis of the Intravascular Imaging Market, 2011-2021
6.5.1 Strengths
6.5.1.1 Provides Cardiologists with Useful Information
6.5.1.2 Higher Resolution Image than Coronary Angiography
6.5.1.3 Strong Intravascular Imaging Pipeline
6.5.2 Weaknesses
6.5.2.1 Expensive Technology That May Limit its Appeal
6.5.2.2 Adds Significant Time and Risk to the Procedure
6.5.3 Opportunities
6.5.3.1 Image Guided Therapy Offers Higher Efficacy than Stenting Alone
6.5.3.2 Increasing Prevalence of Coronary Artery Disease
6.5.4 Threats
6.5.4.1 Small Number of Companies Operate in the Market
6.5.4.2 Low Reimbursement Rates Threaten to Prevent Widescale Use
7. INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ANALYSIS BY COMPANY, 2010
7.1 Boston Scientific
7.1.1 Boston Scientific Interventional Cardiology Sales, 2010
7.1.2 Boston Scientific Interventional Cardiology Rankings, 2010
7.1.3 Boston Scientific Pipeline
7.2 Abbott Vascular
7.2.1 Abbott Vascular Sales, 2010
7.2.2 Abbott Vascular Interventional Cardiology Rankings, 2010
7.2.3 Abbott Vascular Pipeline
7.3 Medtronic
7.3.1 Medtronic Sales, 2010
7.3.2 Medtronic Interventional Cardiology Rankings, 2010
7.3.3 Medtronic Pipeline
7.4 Volcano Corporation
7.4.1 Volcano Corporation Sales, 2010
7.4.2 Volcano Corporation Interventional Cardiology Ranking, 2010
7.4.3 Volcano Corporation Pipeline
7.5 Cordis Corporation (a Johnson & Johnson Company)
7.5.1 Cordis Sales, 2010
7.5.2 Cordis Rankings, 2010
7.5.3 Cordis Pipeline
7.6 St. Jude Medical
7.6.1 St. Jude Medical Sales, 2010
7.6.2 St. Jude Medical Pipeline
8. EXPERT OPINIONS
8.1 Interview with Guillermo Tearney, Professor of Pathology at The Wellman Center for Photomedicine, Harvard Medical School
8.1.1 The Intravascular Imaging Market
8.1.2 The Novel MicroOCT System Currently being Developed by Professor Tearney at Harvard University
8.1.3 The International Working Group for Intracoronary OCT Standardization and Validation
8.2 Interview with Zhongping Chen, Professor of Biomedical Engineering at University of California
8.2.1 The Intravascular Imaging Market
8.2.2 The Combined IVUS/OCT System Currently being Developed by Professor Chen at the University of California
9. CONCLUSIONS
9.1 The Interventional Cardiology Devices Market, 2011-2021
9.1.1 Growth will be Driven by Emerging Markets
9.2 The Coronary Stent Market, 2011-2021
9.2.1 Innovation Will Drive Growth in the DES Market
9.2.2 DES May Be Challenged by Other Stenting Technologies
9.3 The PTCA Balloon Market, 2011-2021
9.3.1 DEBs Will See Rapid Growth
9.4 The Intravascular Imaging Market, 2011-2021
Appendix A
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 2.1 The Cardiology Device Market ($bn) by Sector, 2010
Table 2.2 Advantages and Disadvantages of Interventional Cardiology
Table 3.1 The Interventional Cardiology Devices Market ($bn) by Segments, 2010
Table 3.2 Leading National Markets for Interventional Cardiology Devices ($bn), 2010
Table 3.3 Global Interventional Cardiology Devices Market Forecast ($bn), 2010-2021
Table 3.4 Leading Interventional Cardiology Devices National Market Forecasts ($bn), 2010-2015
Table 3.5 Leading Interventional Cardiology Devices National Market Forecasts ($bn), 2015-2021
Table 3.6 Chinese Interventional Cardiology Devices Market: Drivers and Restraints, 2011-2021
Table 4.1 The DES and BMS Market: Sales ($bn) and Market Share (%), 2010
Table 4.2 The Coronary Stent Market ($bn) by Country/Region, 2010
Table 4.3 The Coronary Stent Market Forecast ($bn), 2010-2015
Table 4.4 The Coronary Stent Market Forecast ($bn), 2015-2021
Table 4.5 Leading Products in the DES Market: Sales ($m) and Market Share (%), 2010
Table 4.6 The DES Market Forecast ($bn), 2010-2015
Table 4.7 The DES Market Forecast ($bn), 2015-2021
Table 4.8 Driver and Restraints in the DES Market, 2011-2015
Table 4.9 Coronary Stents Development Pipeline, 2011
Table 4.10 SWOT Analysis of the DES Market, 2011-2021
Table 5.1 Leading Companies in the PTCA Balloon Market ($bn), 2010
Table 5.2 The PTCA Balloon Market Forecast ($bn), 2010-2015
Table 5.3 The PTCA Balloon Market Forecast ($bn), 2015-2021
Table 5.4 Advantages and Disadvantages of DEBs
Table 5.5 The DEB Market Forecast ($bn), 2010-2015
Table 5.6 The DEB Market Forecast ($bn), 2015-2021
Table 5.7 The DEBs Currently on the Market or in Development, 2011
Table 5.8 SWOT Analysis of the PTCA Balloon Market, 2011-2021
Table 6.1 The Intravascular Imaging Market ($bn) by Segment, 2010
Table 6.2 IVUS Market Share (%) of Volcano Corporation and Boston Scientific by Regions, 2010
Table 6.3 The Intravascular Imaging Market Segments Forecasts ($bn), 2010-2015
Table 6.4 The Intravascular Imaging Market Segments Forecasts ($bn), 2015-2021
Table 6.5 Intravascular Imaging Pipeline, 2011
Table 6.6 SWOT Analysis of the Intravascular Imaging Market, 2011-2021
Table 7.1 Boston Scientific Sales ($bn) by Business Segment, 2010
Table 7.2 Boston Scientific Coronary Stent Sales ($m), 2009 and 2010
Table 7.3 Boston Scientific Rankings by Sales, 2010
Table 7.4 Abbott Laboratories Sales ($bn) by Business Segment, 2010
Table 7.5 Abbott Vascular Rankings by Sales, 2010
Table 7.6 Medtronic Sales ($bn) by Business Segment, 2010 and 2009
Table 7.7 Medtronic Rankings by Sales, 2010
Table 7.8 Volcano Corporation Sales ($m) by Region, 2010 and 2009
Table 7.9 Volcano Corporation Sales ($m) by Business Segment, 2010
Table 7.10 Volcano Corporation Ranking by Sales, 2010
Table 7.11 Cordis Rankings by Sales, 2010
Table 7.12 St. Jude Medical Sales ($bn) by Segment, 2010
Table 9.1 Global Interventional Cardiology Devices Market: Drivers and Restraints, 2011-2021
Table 2.1 The Cardiology Device Market ($bn) by Sector, 2010
Table 2.2 Advantages and Disadvantages of Interventional Cardiology
Table 3.1 The Interventional Cardiology Devices Market ($bn) by Segments, 2010
Table 3.2 Leading National Markets for Interventional Cardiology Devices ($bn), 2010
Table 3.3 Global Interventional Cardiology Devices Market Forecast ($bn), 2010-2021
Table 3.4 Leading Interventional Cardiology Devices National Market Forecasts ($bn), 2010-2015
Table 3.5 Leading Interventional Cardiology Devices National Market Forecasts ($bn), 2015-2021
Table 3.6 Chinese Interventional Cardiology Devices Market: Drivers and Restraints, 2011-2021
Table 4.1 The DES and BMS Market: Sales ($bn) and Market Share (%), 2010
Table 4.2 The Coronary Stent Market ($bn) by Country/Region, 2010
Table 4.3 The Coronary Stent Market Forecast ($bn), 2010-2015
Table 4.4 The Coronary Stent Market Forecast ($bn), 2015-2021
Table 4.5 Leading Products in the DES Market: Sales ($m) and Market Share (%), 2010
Table 4.6 The DES Market Forecast ($bn), 2010-2015
Table 4.7 The DES Market Forecast ($bn), 2015-2021
Table 4.8 Driver and Restraints in the DES Market, 2011-2015
Table 4.9 Coronary Stents Development Pipeline, 2011
Table 4.10 SWOT Analysis of the DES Market, 2011-2021
Table 5.1 Leading Companies in the PTCA Balloon Market ($bn), 2010
Table 5.2 The PTCA Balloon Market Forecast ($bn), 2010-2015
Table 5.3 The PTCA Balloon Market Forecast ($bn), 2015-2021
Table 5.4 Advantages and Disadvantages of DEBs
Table 5.5 The DEB Market Forecast ($bn), 2010-2015
Table 5.6 The DEB Market Forecast ($bn), 2015-2021
Table 5.7 The DEBs Currently on the Market or in Development, 2011
Table 5.8 SWOT Analysis of the PTCA Balloon Market, 2011-2021
Table 6.1 The Intravascular Imaging Market ($bn) by Segment, 2010
Table 6.2 IVUS Market Share (%) of Volcano Corporation and Boston Scientific by Regions, 2010
Table 6.3 The Intravascular Imaging Market Segments Forecasts ($bn), 2010-2015
Table 6.4 The Intravascular Imaging Market Segments Forecasts ($bn), 2015-2021
Table 6.5 Intravascular Imaging Pipeline, 2011
Table 6.6 SWOT Analysis of the Intravascular Imaging Market, 2011-2021
Table 7.1 Boston Scientific Sales ($bn) by Business Segment, 2010
Table 7.2 Boston Scientific Coronary Stent Sales ($m), 2009 and 2010
Table 7.3 Boston Scientific Rankings by Sales, 2010
Table 7.4 Abbott Laboratories Sales ($bn) by Business Segment, 2010
Table 7.5 Abbott Vascular Rankings by Sales, 2010
Table 7.6 Medtronic Sales ($bn) by Business Segment, 2010 and 2009
Table 7.7 Medtronic Rankings by Sales, 2010
Table 7.8 Volcano Corporation Sales ($m) by Region, 2010 and 2009
Table 7.9 Volcano Corporation Sales ($m) by Business Segment, 2010
Table 7.10 Volcano Corporation Ranking by Sales, 2010
Table 7.11 Cordis Rankings by Sales, 2010
Table 7.12 St. Jude Medical Sales ($bn) by Segment, 2010
Table 9.1 Global Interventional Cardiology Devices Market: Drivers and Restraints, 2011-2021
LIST OF FIGURES
Figure 2.1 Market Shares (%) of the Leading Sectors in the Cardiology Device Market, 2010
Figure 3.1 The Interventional Cardiology Devices Market Share (%) by Segments, 2010
Figure 3.2 The Interventional Cardiology Devices Market ($bn) by Segments, 2010
Figure 3.3 The Interventional Cardiology Devices Market Shares (%) in Leading National Markets, 2010
Figure 3.4 Leading National Markets for Interventional Cardiology Devices ($bn), 2010
Figure 3.5 Global Interventional Cardiology Devices Market Forecast ($bn), 2010-2015
Figure 3.6 Global Interventional Cardiology Devices Market Forecast ($bn), 2015-2021
Figure 3.7 The US Interventional Cardiology Devices Market Forecast ($bn), 2010-2015
Figure 3.8 European Interventional Cardiology Devices Market Forecasts ($bn), 2010-2015
Figure 3.9 Asian Interventional Cardiology Devices Market Forecasts ($bn), 2010-2015
Figure 3.10 The US Interventional Cardiology Devices Market Forecast ($bn), 2015-2021
Figure 3.11 European Interventional Cardiology Devices Market Forecasts ($bn), 2015-2021
Figure 3.12 Asian Interventional Cardiology Devices Market Forecasts ($bn), 2015-2021
Figure 4.1 The DES and BMS Market Shares (%), 2010
Figure 4.2 Coronary Stent Market Share (%) by Country/Region, 2010
Figure 4.3 Total Coronary Stent Market Forecast ($bn), 2010-2015
Figure 4.4 Total Coronary Stent Market Forecast ($bn), 2015-2021
Figure 4.5 Market Shares (%) of Leading Products in the DES Market, 2010
Figure 4.6 The DES Market Forecast ($bn), 2010-2015
Figure 4.7 The DES Market Forecast ($bn), 2015-2021
Figure 4.8 Sales ($m) of Taxus Stents by Region, 2010
Figure 4.9 Sales ($m) of Promus Stents by Region, 2010
Figure 5.1 Market Shares (%) of Leading Companies in the PTCA Balloon Market, 2010
Figure 5.2 The PTCA Balloon Market Forecast ($bn), 2010-2015
Figure 5.3 The PTCA Balloon Market Forecast ($bn), 2010-2015
Figure 5.4 The DEB Market Forecast ($bn), 2010-2015
Figure 5.5 The DEB Market Forecast ($bn), 2015-2021
Figure 6.1 The Intravascular Imaging Market Share (%) by Segment, 2010
Figure 6.2 The US IVUS Market Shares (%) by Company, 2010
Figure 6.3 The Japanese IVUS Market Shares (%) by Company, 2010
Figure 6.4 European IVUS Market Shares by Company, 2010
Figure 6.5 Total Intravascular Imaging Market Forecast ($bn), 2010-2015
Figure 6.6 IVUS, OCT and FFR Market Forecasts ($bn), 2010-2015
Figure 6.7 Total Intravascular Imaging Market Forecast ($bn), 2015-2021
Figure 6.8 IVUS, OCT and FFR Market Forecasts ($bn), 2015-2021
Figure 7.1 Boston Scientific Sales Share (%) by Business Segment, 2010
Figure 7.2 Boston Scientific Global Coronary Stent Sales ($m), 2009 and 2010
Figure 7.3 Boston Scientific Coronary Stent Sales ($m) in the US, 2009 and 2010
Figure 7.4 Boston Scientific Coronary Stent Sales ($m) in Markets Outside the US, 2009 and 2010
Figure 7.5 Abbott Laboratories Sales Share (%) by Business Segment, 2010
Figure 7.6 Medtronic Sales Share (%) by Business Segment, 2010
Figure 7.7 Medtronic Sales ($bn) by Business Segment, 2010 and 2009
Figure 7.8 Medtronic Sales ($bn) by Region, 2010
Figure 7.9 Volcano Corporation Sales ($m) by Region, 2010 and 2009
Figure 7.10 Volcano Corporation Sales Share (%) by Region, 2010
Figure 7.11 Volcano Corporation Sales Share (%) by Segment, 2010
Figure 7.12 Cordis Corporation Share (%) of Medical Devices and Diagnostics Segment of J&J, 2010
Figure 7.13 St Jude Medical Sales Share (%) by Segment, 2010
COMPANIES LISTED
Aachen Resonance
Abbott Laboratories
Abbott Vascular
Angiotech Pharmaceuticals
Axsun Technologies
B.Braun Melsungen
Bioabsorbable Vascular Solutions
Biosensors International
Biotronik SE & Co
Blue Medical Devices
Boston Scientific
Bristol Myers Squibb
CeloNova BioSciences
Center for Devices and Radiological Health (CDRH).
Centre for Photomedicine at Massachusetts General Hospital
Circulatory System Devices Panel
ClearStream Technologies
Conor Medsystems
Cordis Corporation
EU Council
Eurocor
Food and Drug Administration (FDA)
Guidant Corporation
Health Canada
InfraReDx
Insightra Medical
Invatec
Johnson & Johnson
JW Medical Systems
Kyoto Medical Planning Co Ltd
Labcoat Limited
LightLab Imaging
Lutonix
Medtronic
MiCell Technologies
MIV Therapeutics
National Institute of Biomedical Imaging and Bioengineering
National Institute of Clinical Excellence (NICE) [UK]
National Institute of Health (NIH) [US]
Novartis
Novelis
OCT Medical Imaging Inc
Opto Circuits ltd
OrbusNeich
Phillips Healthcare
REVA Medical
Sadra Medical
Sanofi-Aventis
Silicon Valley Medical Instruments
St Jude Medical
St Michael's Hospital, Toronto
Terumo Corporation
The International Working Group for Intracoronary OCT Standardization and Validation
The Wellman Center for Photomedicine, Harvard Medical School
University of California at Irvine
Volcano Corporation
Wyeth Pharmaceuticals
Figure 2.1 Market Shares (%) of the Leading Sectors in the Cardiology Device Market, 2010
Figure 3.1 The Interventional Cardiology Devices Market Share (%) by Segments, 2010
Figure 3.2 The Interventional Cardiology Devices Market ($bn) by Segments, 2010
Figure 3.3 The Interventional Cardiology Devices Market Shares (%) in Leading National Markets, 2010
Figure 3.4 Leading National Markets for Interventional Cardiology Devices ($bn), 2010
Figure 3.5 Global Interventional Cardiology Devices Market Forecast ($bn), 2010-2015
Figure 3.6 Global Interventional Cardiology Devices Market Forecast ($bn), 2015-2021
Figure 3.7 The US Interventional Cardiology Devices Market Forecast ($bn), 2010-2015
Figure 3.8 European Interventional Cardiology Devices Market Forecasts ($bn), 2010-2015
Figure 3.9 Asian Interventional Cardiology Devices Market Forecasts ($bn), 2010-2015
Figure 3.10 The US Interventional Cardiology Devices Market Forecast ($bn), 2015-2021
Figure 3.11 European Interventional Cardiology Devices Market Forecasts ($bn), 2015-2021
Figure 3.12 Asian Interventional Cardiology Devices Market Forecasts ($bn), 2015-2021
Figure 4.1 The DES and BMS Market Shares (%), 2010
Figure 4.2 Coronary Stent Market Share (%) by Country/Region, 2010
Figure 4.3 Total Coronary Stent Market Forecast ($bn), 2010-2015
Figure 4.4 Total Coronary Stent Market Forecast ($bn), 2015-2021
Figure 4.5 Market Shares (%) of Leading Products in the DES Market, 2010
Figure 4.6 The DES Market Forecast ($bn), 2010-2015
Figure 4.7 The DES Market Forecast ($bn), 2015-2021
Figure 4.8 Sales ($m) of Taxus Stents by Region, 2010
Figure 4.9 Sales ($m) of Promus Stents by Region, 2010
Figure 5.1 Market Shares (%) of Leading Companies in the PTCA Balloon Market, 2010
Figure 5.2 The PTCA Balloon Market Forecast ($bn), 2010-2015
Figure 5.3 The PTCA Balloon Market Forecast ($bn), 2010-2015
Figure 5.4 The DEB Market Forecast ($bn), 2010-2015
Figure 5.5 The DEB Market Forecast ($bn), 2015-2021
Figure 6.1 The Intravascular Imaging Market Share (%) by Segment, 2010
Figure 6.2 The US IVUS Market Shares (%) by Company, 2010
Figure 6.3 The Japanese IVUS Market Shares (%) by Company, 2010
Figure 6.4 European IVUS Market Shares by Company, 2010
Figure 6.5 Total Intravascular Imaging Market Forecast ($bn), 2010-2015
Figure 6.6 IVUS, OCT and FFR Market Forecasts ($bn), 2010-2015
Figure 6.7 Total Intravascular Imaging Market Forecast ($bn), 2015-2021
Figure 6.8 IVUS, OCT and FFR Market Forecasts ($bn), 2015-2021
Figure 7.1 Boston Scientific Sales Share (%) by Business Segment, 2010
Figure 7.2 Boston Scientific Global Coronary Stent Sales ($m), 2009 and 2010
Figure 7.3 Boston Scientific Coronary Stent Sales ($m) in the US, 2009 and 2010
Figure 7.4 Boston Scientific Coronary Stent Sales ($m) in Markets Outside the US, 2009 and 2010
Figure 7.5 Abbott Laboratories Sales Share (%) by Business Segment, 2010
Figure 7.6 Medtronic Sales Share (%) by Business Segment, 2010
Figure 7.7 Medtronic Sales ($bn) by Business Segment, 2010 and 2009
Figure 7.8 Medtronic Sales ($bn) by Region, 2010
Figure 7.9 Volcano Corporation Sales ($m) by Region, 2010 and 2009
Figure 7.10 Volcano Corporation Sales Share (%) by Region, 2010
Figure 7.11 Volcano Corporation Sales Share (%) by Segment, 2010
Figure 7.12 Cordis Corporation Share (%) of Medical Devices and Diagnostics Segment of J&J, 2010
Figure 7.13 St Jude Medical Sales Share (%) by Segment, 2010
COMPANIES LISTED
Aachen Resonance
Abbott Laboratories
Abbott Vascular
Angiotech Pharmaceuticals
Axsun Technologies
B.Braun Melsungen
Bioabsorbable Vascular Solutions
Biosensors International
Biotronik SE & Co
Blue Medical Devices
Boston Scientific
Bristol Myers Squibb
CeloNova BioSciences
Center for Devices and Radiological Health (CDRH).
Centre for Photomedicine at Massachusetts General Hospital
Circulatory System Devices Panel
ClearStream Technologies
Conor Medsystems
Cordis Corporation
EU Council
Eurocor
Food and Drug Administration (FDA)
Guidant Corporation
Health Canada
InfraReDx
Insightra Medical
Invatec
Johnson & Johnson
JW Medical Systems
Kyoto Medical Planning Co Ltd
Labcoat Limited
LightLab Imaging
Lutonix
Medtronic
MiCell Technologies
MIV Therapeutics
National Institute of Biomedical Imaging and Bioengineering
National Institute of Clinical Excellence (NICE) [UK]
National Institute of Health (NIH) [US]
Novartis
Novelis
OCT Medical Imaging Inc
Opto Circuits ltd
OrbusNeich
Phillips Healthcare
REVA Medical
Sadra Medical
Sanofi-Aventis
Silicon Valley Medical Instruments
St Jude Medical
St Michael's Hospital, Toronto
Terumo Corporation
The International Working Group for Intracoronary OCT Standardization and Validation
The Wellman Center for Photomedicine, Harvard Medical School
University of California at Irvine
Volcano Corporation
Wyeth Pharmaceuticals
